A.M. Granov Russian research Center for Radiology and Surgical Technologies
https://doi.org/10.37174/2587-7593-2019-2-1-84-90
Abstract
We demonstrate the clinical case of malignant pancreatic insulinoma. The diagnostic algorythm in gastroenteropancreatic neuroendocrine tumors and measures, taken on different stages of treatment, are described. We show the potential of 68Ga-DOTA-TATE positron-emission tomography combined with computed tomography in locating insulinoma, which is very difficult to find, using standart visualisation techniques. 68Ga-DOTA-TATE is a new radiotracer, synthetic somatostatin analogue. The article comes with a short literature review.
About the Authors
D. A. Granov
A.M. Granov Russian research Center for Radiology and Surgical Technologies
Russian Federation
Russian Federation
S.-Petersburg
M. S. Tlostanova
A.M. Granov Russian research Center for Radiology and Surgical Technologies
Russian Federation
Russian Federation
S.-Petersburg
S. V. Shapoval
A.M. Granov Russian research Center for Radiology and Surgical Technologies
Russian Federation
Russian Federation
S.-Petersburg
S. A. Popov
A.M. Granov Russian research Center for Radiology and Surgical Technologies
Russian Federation
Russian Federation
S.-Petersburg
N. A. Nosov
A.M. Granov Russian research Center for Radiology and Surgical Technologies
Russian Federation
Russian Federation
S.-Petersburg
M. V. Ignatova
A.M. Granov Russian research Center for Radiology and Surgical Technologies
Russian Federation
Russian Federation
S.-Petersburg
References
1. Halfdanarson T.R., Rabe K.G., Rubin J. et al. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival // Ann. Oncology. 2008. Vol. 19. P. 1727-1733.
2. Oberg K., Eriksson B. Endocrine tumours of the pancreas // Best Practice & Research Clin. Gastroenterol. 2005. Vol. 19. P. 753-781.
3. Клиническая эндокринология. Руководство. 3-е изд. Под ред. Н.Т. Старковой. - СПб.: Питер, 2002. 576 с.
4. Pavel M., O’Toole D., Costa F. et al. ENETS Consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site // Neuroendocrinology. 2016. Vol. 103. P. 172-185.
5. de Herder W.W., Niederle B., Scoazec J.Y. et al. Welldifferentiated pancreatic tumor/carcinoma: insulinoma // Neuroendocrinology. 2006. Vol. 84. P. 183-188.
6. Lloyd R.V. Utility of Ki-67 as a prognostic marker in pancreatic endocrine neoplasms // Amer. J. Clin. Pathol. 1998. Vol. 109. P. 245-247.
7. Egorov A.V. Factors determining the immediate results of surgical treatment of insulin producing pancreatic tumors // In: Modern Aspects of Surgical Endocrinology. Smolensk. 2002. P. 192-194.
8. Kwekkeboom D.J., Krenning E.P. Somatostatin receptor imaging // Sem. Nucl. Med. 2002. Vol. 32. № 2. P 84-91.
9. Virgolini I., Gabriel M., Kroiss A., von Guggenberg E. Current knowledge on the sensitivity of the 68Ga-somatostatin receptor positron emission tomography and the SUV reference range for management of pancreatic neuroendocrine tumours // Eur. J. Nucl. Med. Mol. Imaging. 2016. Vol. 43. № 11. P 2072-2083.
10. Xu C., Zhang H. somatostatin receptor based imaging and radionuclide therapy // Biomed. Res. Int. 2015. P 917968.
11. Kaklamanos I.G., Bathe O.F., Sfakianakis G.N., Nadji M. Malignant Insulinoma Metastatic to the Breast // Endocrinologist. 2000. Vol. 10. P. 211-212.
Review
For citations:
Granov D.A., Tlostanova M.S., Shapoval S.V., Popov S.A., Nosov N.A., Ignatova M.V. A.M. Granov Russian research Center for Radiology and Surgical Technologies. Journal of oncology: diagnostic radiology and radiotherapy. 2019;2(1):84-90. (In Russ.) https://doi.org/10.37174/2587-7593-2019-2-1-84-90
Views:
1138
Email this article 